Actionable news
0
All posts from Actionable news
Actionable news in DBVT: DBV TECHNOLOGIES S.A.,

2 Cell Subset Specific to Allergy

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its investigational treatment for peanut allergy, AR101, was highlighted in a recent publication by Benaroya Research Institute at Virginia Mason focused on the discovery of an immune cell subset — TH2A cells – that appears to be involved in the pathogenesis of allergies. These allergen-specific T cells are present in people with allergies but nearly entirely absent from people without allergies.

“We’re committed to advancing the understanding of food allergy and very pleased to see these data from our ongoing collaboration with Benaroya Research Institute and Dr. Erik Wambre published”

The publication, which appeared in the August 2 issue of Science Translational Medicine, also reported that, in a small pilot experiment, AR101 treatment was associated with a significant reduction of TH2A cells in blood samples from a subset of peanut-allergic patients from Aimmune’s ARC001 trial. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy.

“We’re hopeful that the identification of these TH2A cells will give researchers a tool to help improve medicine’s ability to diagnose, monitor and treat allergies,” said Dr. Wambre. “With the samples from the ARC001 trial, we saw targeted elimination of peanut-specific TH2A cells after only six months of AR101 therapy. Specifically, patients receiving AR101 experienced statistically significant reductions in TH2A cells, whereas there was no reduction in TH2A cells in patients receiving placebo. These TH2A cell reductions appeared to be associated with clinical response. Though this preliminary experiment was small, the results were clear, and we are excited to analyze the data from Aimmune’s much larger, ongoing Phase 3 PALISADE population. If...


More